Ainos, Inc.

Equities

AIMD

US00902F3038

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 02:08:28 2024-05-14 pm EDT			5-day change	1st Jan Change
1.04 ^USD	-1.89%		-4.26%	-49.09%

May. 13	Earnings Flash (AIMD) AINOS Reports Q1 Revenue $20,729	MT
Mar. 19	Ainos, Inc. Appoints Christopher Hsin-Liang Lee as Chief Financial Officer	CI

Ainos, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022

August 15, 2022 at 06:26 am EDT

Ainos, Inc. reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported sales was USD 0.636627 million compared to USD 0.202992 million a year ago. Net loss was USD 1.95 million compared to USD 0.749774 million a year ago. Basic loss per share from continuing operations was USD 0.15 compared to USD 0.15 a year ago. Diluted loss per share from continuing operations was USD 0.15 compared to USD 0.15 a year ago.
For the six months, sales was USD 0.723828 million compared to USD 0.205113 million a year ago. Net loss was USD 4.05 million compared to USD 1.28 million a year ago. Basic loss per share from continuing operations was USD 0.45 compared to USD 0.3 a year ago. Diluted loss per share from continuing operations was USD 0.45 compared to USD 0.3 a year ago.

Latest news about Ainos, Inc.

Earnings Flash (AIMD) AINOS Reports Q1 Revenue $20,729	May. 13	MT
Ainos, Inc. Appoints Christopher Hsin-Liang Lee as Chief Financial Officer	Mar. 19	CI
Ainos, Inc. Announces Resignation of Meng-Lin Sung, the Chief Financial Officer	Mar. 15	CI
Traders Anticipate Inflation Report as US Equities Open Lower on Wall Street	Mar. 11	MT
Top Premarket Decliners	Mar. 11	MT
Ainos, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 08	CI
Top Premarket Gainers	Mar. 08	MT
Ainos Submits Clinical Hold Complete Response to US FDA to Address Issues in Phase 2 Veldona Trial	Feb. 05	MT
Ainos, Inc. Submits Clinical Hold Complete Response to US FDA to Resolve the Deficiencies on Investigational New Drug Phase Ii Trial of Its Veldona Formulation Against Mild Covid-19 Symptoms	Feb. 05	CI
Ainos, Inc. Enters into Five-Year Product Development Agreement with Taiwan Carbon Nano Technology Corporation	Jan. 12	CI
Wall Street Set to Open Lower as Monthly Jobs Data Much Stronger Than Expected	Jan. 05	MT
Ainos Regains Compliance With Nasdaq Listing Rule	Jan. 02	MT
Ainos, Nisshinbo Micro Devices and Inabata Initiate Phase 2 of VOC Co-Development Powered by Ai Nose, Accelerating the Digitalization of Smell	Dec. 26	CI
Ainos, Inc. Announces Resignation of John Junyong Lee as Chief Legal Counsel and Corporate Secretary	Dec. 22	CI
Ainos Says Three Clinical Studies for Veldona Show 'Positive' Data	Nov. 21	MT
Ainos, Inc. Announces Positive Data Reports from its Clinical Studies for VELDONA as Potential Treatment of Oral Warts in HIV-Seropositive Patients, an Orphan Drug Designated by the FDA	Nov. 21	CI
Earnings Flash (AIMD) AINOS Reports Q3 Revenue $24,489	Nov. 09	MT
Ainos, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
Ainos, Inc. Signs MoU for Contract Clinical Trials to Conduct Clinical Study of Potential New Animal Drug Based on Veldona	Nov. 06	CI
Ainos to Issue Preliminary $3 Million Portion of Expected $10 Million Notes Placement	23-09-25	MT
Ainos Says Candidate Treatment for HIV Oral Warts Gets Orphan Drug Designation	23-09-18	MT
Ainos, Inc. Commences Shipping its VELDONA Pet Cytoprotein Supplements in Taiwan	23-09-05	CI
Earnings Flash (AIMD) AINOS Reports Q2 Revenue $28,555	23-08-11	MT
Ainos, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-11	CI
Ainos Partners with Nisshinbo Micro Devices and Inabata to Co-Develop VOC Sensing Platform for Broader Industry Adoption	23-08-10	CI

Chart Ainos, Inc.

Duration

Period

More charts

Company Profile

Ainos, Inc. is a diversified healthcare company, which is focused on the development of point-of-care testing (POCT), low-dose VELDONA interferon therapeutics and synthetic Ribonucleic Acid (RNA)-driven preventative medicine. The Company's products include VELDONA clinical-stage human therapeutics, VELDONA Pet cytoprotein health supplements, and telehealth-friendly POCTs powered by its AI Nose technology platform. VELDONA Pet is formulated to address a variety of health issues in dogs and cats, including skin, gum, emotion, discomfort caused by allergies, eye, and weight-related issues. Its pipeline of products, which are under development, includes VELDONA human drugs, VOC POCT-Ainos Flora, VOC platform-NISD co-development, VOC POCT-Ainos Pen, VOC POCT-CHS430 and Synthetic RNA. VELDONA human drugs are the high-priority programs include oral warts for human immunodeficiency virus seropositive patients, common cold, influenza, Sjogrens syndrome and treatment for mild COVID-19 symptoms.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
AINOS, INC.	-49.09%	6.51M
VERTEX PHARMACEUTICALS INCORPORATED	+4.19%	111B
REGENERON PHARMACEUTICALS, INC.	+11.47%	105B
BIONTECH SE	-13.00%	22.34B
ARGENX SE	-3.70%	21.93B
GENMAB A/S	-6.03%	18.59B
WUXI APPTEC CO., LTD.	-35.21%	18.12B
BEIGENE, LTD.	-10.29%	16.96B
NEUROCRINE BIOSCIENCES, INC.	+3.30%	13.7B
SAREPTA THERAPEUTICS, INC.	+36.99%	12.45B

Bio Therapeutic Drugs